Meeting
2016 ASCO Annual Meeting
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience.
Authors
Ugo De Giorgi
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Ugo De Giorgi , Sandrine Richard , Manuela Badoglio , Edward Kanfer , Jean Henri Bourrhis , Emmanuelle Nicolas-Virelizier , Bruno Lioure , Kim Vettenranta , Sonja Martin , Peter Dreger , Markus Kajo Schuler , Emanuela Scarpi , Giovanni Rosti , Frédéric Selle , Francesco Lanza , Marco Bregni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5558)
DOI
10.1200/JCO.2016.34.15_suppl.5558
Abstract #
5558
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Genitourinary Cancers Symposium
High doses of chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory testicular germ cell tumors: Multicenter real-world experience in Argentina.
First Author: Federico Losco
Poster
2022 ASCO Annual Meeting
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
First Author: Fadi Taza